(+/-)-Pentaacetylcatechin

(+/-)-Pentaacetylcatechin

SCHEMBL14701425

CC(=O)Oc1cc(OC(C)=O)c2c(c1)OC(c1ccc(OC(C)=O)c(OC(C)=O)c1)[C@H](OC(C)=O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 1.00
CYP3A4 P08684 1/20 1.00
MAPK1 P28482 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
ABCB1 P08183 8/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
MAPT P10636 1/20 0.67
STING1 Q86WV6 3/20 0.57
GABRA1 P14867 3/20 0.53
GABRB2 P47870 3/20 0.53
F10 P00742 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+/-)-Pentaacetylcatechin SCHEMBL719420 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
Epicatechin Pentaacetate SCHEMBL14691288 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
Catechin Pentaacetate SCHEMBL719419 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL5367055 0.92 CYP3A4 (0.84) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL5109161 0.90 ALDH1A1 (0.81) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL4671149 0.90 ALDH1A1 (0.81) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL23135645 0.88 ABCB1 (0.84) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL6702376 0.87 CYP3A4 (0.77) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL14701484 0.87 CYP3A4 (0.77) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1
SCHEMBL16838244 0.86 ALDH1A1 (0.75) ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187448-B2 Flavonoid compounds CARDERO THERAPEUTICS, INC. (US) 2015-11-17 US disclosed
US-9187448-B2 Flavonoid compounds CARDERO THERAPEUTICS, INC. (US) 2015-11-17 US disclosed
US-20140256741-A1 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2014-09-11 US disclosed
US-20140256741-A1 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2014-09-11 US disclosed
WO-2013022846-A2 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2013-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256741-A1 FLAVONOID COMPOUNDS FIS1, TFAM, MFN2 ALDH1A1 1984/4885CYP3A4 3740/4885MAPK1 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.